Could Biomarin Pharma Incorporated (NASDAQ:BMRN) Change Direction After More Shorts?

September 17, 2017 - By Hazel Jackson

 Could Biomarin Pharma Incorporated (NASDAQ:BMRN) Change Direction After More Shorts?

Investors sentiment decreased to 1.04 in Q4 2016. Its down 0.62, from 1.66 in 2016Q3. It dropped, as 50 investors sold BioMarin Pharmaceutical Inc. shares while 129 reduced holdings. 50 funds opened positions while 136 raised stakes. 165.79 million shares or 0.67% more from 164.68 million shares in 2016Q3 were reported.
Geode Management Ltd stated it has 0.05% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Neuberger Berman Grp Incorporated Limited holds 0.02% or 158,898 shares in its portfolio. Dimensional Fund Advisors L P stated it has 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). The Pennsylvania-based Pnc Ser Group has invested 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Northwestern Mutual Wealth Commerce reported 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Kopp Investment Advsrs Limited Liability Corp stated it has 11,098 shares. Nippon Life Company holds 8,865 shares. Cubist Systematic Strategies Limited Liability Corp reported 0% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Torray Limited Liability Corporation stated it has 2.21% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Citigroup Incorporated has invested 0.01% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Winslow Evans Crocker invested in 78 shares or 0% of the stock. Primecap Mngmt Ca has invested 0.64% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Loring Wolcott Coolidge Fiduciary Advsr Llp Ma owns 1,100 shares or 0% of their US portfolio. Thompson Davis & Incorporated stated it has 0.02% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Amer Century Incorporated accumulated 0.03% or 391,835 shares.

Since March 29, 2017, it had 0 insider buys, and 15 selling transactions for $8.25 million activity. On Friday, June 16 LAWLIS V BRYAN sold $337,500 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 3,750 shares. 9,471 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares with value of $862,230 were sold by Davis George Eric. On Friday, June 16 FUCHS HENRY J sold $1.35 million worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 15,000 shares. 1,004 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares with value of $89,968 were sold by Ajer Jeffrey Robert. On Friday, April 28 Mueller Brian sold $687,334 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 7,482 shares.

The stock of Biomarin Pharma Incorporated (NASDAQ:BMRN) registered an increase of 7.25% in short interest. BMRN’s total short interest was 8.04 million shares in September as published by FINRA. Its up 7.25% from 7.50 million shares, reported previously. With 1.18M shares average volume, it will take short sellers 7 days to cover their BMRN’s short positions. The short interest to Biomarin Pharma Incorporated’s float is 4.68%.

The stock increased 0.75% or $0.68 on September 15, reaching $91.91. About 1.76M shares traded or 24.82% up from the average. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since September 17, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

BioMarin Pharmaceutical Inc. is a biotechnology company. The company has market cap of $16.11 billion. The Firm develops and commercializes pharmaceuticals for various diseases and medical conditions. It currently has negative earnings. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 25 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 17 have Buy rating, 0 Sell and 8 Hold. Therefore 68% are positive. BioMarin Pharmaceutical had 61 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Piper Jaffray given on Monday, November 7. Goldman Sachs initiated the shares of BMRN in report on Wednesday, November 18 with “Buy” rating. The firm has “Outperform” rating given on Monday, January 23 by Credit Suisse. As per Thursday, August 3, the company rating was maintained by Stifel Nicolaus. Deutsche Bank maintained it with “Buy” rating and $160 target in Wednesday, August 5 report. The firm earned “Overweight” rating on Friday, August 5 by Barclays Capital. The stock has “Buy” rating by RBC Capital Markets on Monday, August 24. The company was reinitiated on Thursday, September 14 by PiperJaffray. BMO Capital Markets maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, July 6 with “Buy” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Perform” rating by Oppenheimer on Wednesday, November 25.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Zacks.com which released: “BioMarin (BMRN) Up 2.5% Since Earnings Report: Can It Continue?” on September 07, 2017, also Prnewswire.com with their article: “FDA Accepts BioMarin’s Pegvaliase Biologics License Application (BLA) and …” published on August 29, 2017, Prnewswire.com published: “BioMarin Announces Exercise in Full of Underwriters’ Option to Purchase …” on August 23, 2017. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Investorplace.com and their article: “3 Big Stock Charts for Wednesday: Twilio Inc (TWLO), BioMarin Pharmaceutical …” published on August 23, 2017 as well as Seekingalpha.com‘s news article titled: “No Ad Com planned for BioMarin’s pegvaliase” with publication date: September 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.